

Regional Drugs Testing Laboratory

Directorate General of Health Services, Guwahati (India) - 781022 Fax: 0361-2338555/2330555 Phone No.0361 2338555

Email:rdtlquwahati@cdsco.nic.in

FORM 13 (See rule 46)

CERTIFICATE OF TEST OR ANALYSIS BY GOVERNMENT ANALYST UNDER SECTION 25(1) OF THE DRUGS AND COSMETICS ACT, 1940

1. Name of Inspector from whom received

: TIMOTHY THANCHUNGNUNGA, Assistant Director (F

GOVt.O

India

and D) State FDA

Kulikawn, Aizawl- 796005

2. Serial No. and date of Inspector's memorandum

: B.11012/5/2024-CMO (W)/DRUGS/36, 21-JAN-2025

3. Number of Sample

: SMP/MZ/TMT/2024-2025/031

4. Date of receipt

: 03-FEB-2025

5. Names of drugs purporting to be contained in the sample : CO-TRIMOXAZOLE ORAL SUSPENSION IP

(SEPTRAN PAEDIATRIC SUSPENSION 60 ml)

Lab. Sample No.	Report No.	Batch No.	Date of Mfg.	Date of Exp.	Mfg. By
LSD/GUW/2024- 25/1736	GUW/LS/2024- 25/1770	SH3862431	Sep-2024		Sanpras Healthcare Pvt. Ltd.,, Plot No.81, STICE, Musalgaon Sinnar, Dist. Nashik -422112. (INDIA)

6. Condition of seals on

[the packet or on portion of sample or container]

Seals were intact & identical to the specimen impression of the seal received

from Drugs Inspector

7. Result of test or analysis with protocols or test or analysis applied : Please see below

Date of Testing: From 18-Feb-2025 To 19-Feb-2025

COMPOSITION

Each 5 ml is purported to contain Trimethoprim IP 40 mg and

Sulphamethoxazole iP 200 mg.

Protocol Applied: I.P. 2022

Sr No.	Test Name	Result	NA Limits	
1	Description	Pink colored suspension filled in amber colored plastic bottles.		
2	Identification	Gives positive test for Trimethoprim and Sulphamethoxazole.	NA	
3	Weight per ml	1.1329 g/ml	NA	
4	pH	5.94	5,to 6.5.	

<u>Assay</u>

Sr.No	Ingredient Name	Found	Claim	% of claim	Limits	Procedure / Method
1	Trimethoprim	38.64 mg/5ml	40 mg/5ml	96.6	90 % to 110 %	I.P. 2022
æ	id.					

2	Sulphamethoxazole	181.71 mg/5ml	200 mg/5ml	90.855	90 % to 110 %	I.P. 2022	Í
he opini	on of the undersigned Act, 1940, and Rules tl	the sample referre	d to above is	of standard	quality as defined in t	he Drugs and	-

The sample conform to claim as per I.P. 2022 in respect of test performed.

Date: 24-FEB-2025

GOVERNMENT ANALYST Rinku Kalita Government Analyst R.D.T.L., Guwahati-22

END OF REPORT ------